The present invention belongs to the technical field of medicines, relates to an NLRP3 inflammasome inhibitor and use thereof, and particularly relates to a compound of general formula (I), or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, wherein each group is defined in the specification. Researches show that the compound of general formula (I), or pharmaceutically acceptable salt, the stereoisomer or the tautomer thereof has relatively high biological activity on NLRP3 inflammasomes and has an important clinical development value for the treatment of NLRP3-associated diseases.

##STR00001##

Provided are a substituted heteroaryl phthalazine derivative as shown in formula (I-0), a use thereof as an NLRP3 inhibitor, and a preparation method therefor; the derivative has relatively good NLRP3 inhibitory activity.

##STR00001##

Provided are a substituted heteroaryl phthalazine derivative as shown in formula (I-0), a use thereof as an NLRP3 inhibitor, and a preparation method therefor; the derivative has relatively good NLRP3 inhibitory activity.

##STR00001##

The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R.sup.1, R.sup.2A, R.sup.2B, R.sup.2C, R.sup.2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.

##STR00001##

The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

##STR00001##

The invention provides for compounds of formula (I)

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

The invention provides for compounds of formula (I)

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

A compound represented by formula (I), a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of the pharmaceutically acceptable salt thereof, a preparation method therefor and an application thereof. The nitrogen-containing compound has good inhibitory activity against NLRP3.

##STR00001##

A compound represented by formula (I), a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of the pharmaceutically acceptable salt thereof, a preparation method therefor and an application thereof. The nitrogen-containing compound has good inhibitory activity against NLRP3.

##STR00001##

Disclosed are compounds of Formula (I): ##STR00001##
or pharmaceutically acceptable salts or solvates thereof, wherein R.sup.1, R.sup.3, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.